L&K Biomed Secures FDA Approval for BluEX-C Height-Expandable Cervical Cage

Product image of the cervical height-expansion cage ‘BluEX-C’. Provided by L&K Bio

L&K Biomed, a company specializing in spinal implants, has received approval from the U.S. Food and Drug Administration (FDA) for its height-expandable cervical cage, 'BluEX-C,' accelerating its efforts to penetrate the global cervical spine market.

The company announced on May 19 that it obtained final FDA approval for BluEX-C on May 16 (local time), approximately two months after filing for approval in March.

The height-expandable cervical cage is regarded as a highly complex product category, as it must deliver both precise expansion mechanisms and stability within the narrow cervical space. Due to structural constraints and the high level of technical difficulty, there have been few cases of FDA approval and commercialization in this field.

The company explained that this early approval once again demonstrates the product’s completeness and technological competitiveness.

L&K Biomed has been pursuing its ‘New Cervical Project’ with the goal of expanding its presence in the global cervical market. Following FDA approval for its cervical plate fixation system, the 'Castleloc-P Anterior Cervical Plate System,' the company has now secured approval for BluEX-C, completing the foundational phase of the project.

By expanding its portfolio from existing lumbar height-expandable products to include cervical devices, the company aims to further strengthen its position in the global cervical spine market.

The newly approved 'BluEX-C' offers various height options, adjustable from 4mm up to a maximum of 15mm upon expansion. It is designed to allow more precise choices tailored to the patient’s anatomical structure and the surgical environment.

The company noted that such a broad range of size options is rare even in the global market. By improving features that previously acted as barriers during hospital registration processes, L&K Biomed expects to broaden hospital adoption of the device.

With the global spinal implant market continuing to grow, the market for height-expandable cervical cages is also rapidly attracting attention. The global spinal implant market is estimated to be worth approximately $13 billion (about 18 trillion won), with cervical fusion procedures accounting for roughly 40% of that market.

In particular, in the U.S. market, anterior cervical discectomy and fusion (ACDF) has become one of the standard surgical methods, and analysts say the market continues to expand based on steady surgical demand.

An L&K Biomed representative stated, "Height-expandable cervical cages are products that must deliver both a precise expansion mechanism and stability within a small structure, so the number of commercialized products is limited. This FDA approval is more than just an addition to our product lineup; it is proof of our unrivaled technological capability and development competency."

They added, "We expect that, based on these rare and innovative products, we can further strengthen our penetration in the U.S. market alongside our existing product lineup. We plan to translate this into tangible sales results by ramping up local marketing and sales activities."

L&K Biomed also plans to apply for FDA approval for its 'Stand-alone Cervical Expandable Cage' within this year, completing a full lineup of cervical products.

This latest FDA approval is seen as evidence that L&K Biomed is expanding its height-expandable spinal implant portfolio from the lumbar to the cervical segment, marking a full-fledged push into the global spinal implant market.

This content was produced with the assistance of AI translation services.